Navigation Links
Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT
Date:5/11/2009

CHENGDU, China, May 11 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that management will hold a conference call to discuss its 2009 fiscal third quarter at 11:00 a.m. EDT on Friday, May 15, 2009. Financial results will be released on May 14, 2009 after the market closes.

Interested parties may access the call by dialing +1-877-941-2927 from within the United States, or +1-480-629-9725 if calling internationally. The conference ID is 4076664. It is advisable to dial in approximately 5-10 minutes prior to the start of the call. A replay will be available through May 29, 2009 and can be accessed by dialing +1-800-406-7325 (U.S.), +1-303-590-3030 (Int'l), passcode 4076664.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at http://www.viavid.net or at the following link: http://viavid.net/dce.aspx?sid=00006448 . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web:  http://www.hcinternational.net

'/>"/>
SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
2. Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders
3. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
4. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
5. Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program
6. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
7. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
8. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
9. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
11. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 , ... ... “ How CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” ... an eye on reducing its spend on provider-administered drugs while preserving care provided to ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... 2016 Glycotope GmbH, a clinical-stage ... the appointment of Dr. Alfredo Zurlo as ... oncologist with many years clinical experience and a proven ... last role was at Mologen AG where he was ... Previously Dr. Zurlo held various positions at F Hoffmann ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: